Cymbalta Approvability Hurdles Began With Manufacturing, Ended With Liver Safety
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Key issues from FDA’s "approvable" letters for Cymbalta. The agency’s initial concerns were manufacturing-focused; the second letter reflects the emerging concerns regarding hepatotoxicity.